Show Me the Money: Why Companies Overpay MCOs--and How They Can Stop
To get on formularies, drug companies pay MCOs too much in rebates and get too little market share in return. But "fair share" analysis can help yield big revenue gains as well as giving drug companies the tools to make business-improving tradeoffs within their product portfolios. Key analyses and related interventions can help return to manufacturers some of the market power and negotiating leverage that is shifting from pharma companies to MCOs.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.